Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Thyroid Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Follicular 1Lung Neoplasms 1Hypothyroidism 1Hepatic Encephalopathy 1Goiter 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Temozolomide 69Bevacizumab 40Radiotherapy 22Magnetic Resonance Spectroscopy 20Irinotecan 17Specimen Handling 10Carboplatin 10Carmustine 9X-Rays 7Radiation 7olaparib 6Surgical Procedures, Operative 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Nivolumab 6Everolimus 6Cyclophosphamide 6Biopsy 6trametinib 5Thalidomide 5Cisplatin 5pembrolizumab 4palbociclib 4fluorodopa F 18 4erdafitinib 4dabrafenib 4Lomustine 4Etoposide 4Drug Therapy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Glioma × Glucose × Clear all
NCT06855628 2025-10-28

Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

Stanford University

Phase 2 Suspended
10 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡